Pharmasset will host a conference call at 1:00 PM ET (US) and 7:00 PM
CEST (Milan) on Friday, April 25, 2008 to discuss the addition of two R7128
cohorts, as well as the results of the 4-week combination study of R7128
presented at EASL.
US/Canada Toll-Free callers: +1 (877) 545-1490
US/Canada Toll or International Toll callers: +1 (719) 325-4884
Live audio of the conference call will be simultaneously broadcast over the internet via a webcast. To access the live webcast, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's corporate website at http://investor.pharmasset.com/events.cfm.
Please connect to the company's website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary to listen to the webcast. The archived replay of the webcast will be available on the Pharmasset website for two weeks following the conference call.
R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.
R7128 demonstrated potent, dose-dependent antiviral activity across
four prior treatment-failure patient cohorts (n=40) receiving 750 mg or
1500 mg administered either once-daily or twice-daily for 14 days as
|SOURCE Pharmasset, Inc.|
Copyright©2008 PR Newswire.
All rights reserved